Catalent Pharma Solutions announced that InterveXion has enrolled the first patient in STAMPOUT, the first trial in methamphetamine users of the first-in-class anti-methamphetamine antibody IXT-m200. STAMPOUT will be a phase 2a, parallel-group, placebo-controlled, double-blind study of the effect of IXT-m200 on methamphetamine pharmacokinetics and subjective effects in methamphetamine users.
 
Catalent has supported InterveXion by engineering the cell line which expresses the drug’s antibody employing its proprietary GPEx® technology and completing process development. Catalent provided cGMP manufacturing for the clinical trial at the company’s Madison, Wisconsin, biomanufacturing facility.
 
IXT-m200, a monoclonal antibody that specifically binds methamphetamine in the blood, is being developed as a pharmacological treatment for use in conjunction with behavioral therapies. IXT- m200 is expected to alter methamphetamine pharmacokinetics in human subjects resulting in reduced or blocked subjective effects that reinforce methamphetamine use. STAMPOUT will provide proof-of-concept that IXT-m200 can alter methamphetamine disposition. This will be the first clinical study of a biological medication in methamphetamine users. 
 
“Methamphetamine addiction is a serious global healthcare burden, and we are pleased to be working with InterveXion on this important treatment,” commented Mike Riley, vice president and general manager of Drug Substance and Bioanalytical services for Catalent Biologics. “We continue to work closely with innovative organizations such as InterveXion to bring potentially life-changing products to patients.”